Drug Profile

GLPG 0259

Alternative Names: GLPG0259

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Galapagos NV
Class Antirheumatics; Small molecules
Mechanism of Action MAP-kinase-activated kinase 5 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Rheumatoid arthritis

Most Recent Events

09 Nov 2011 Efficacy & adverse events data from a phase II trial in Rheumatoid arthritis presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2011)
15 Apr 2011 Discontinued - Phase-II for Rheumatoid arthritis in Belgium (PO)
15 Apr 2011 Discontinued - Phase-II for Rheumatoid arthritis in Netherlands (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com